Low-dose chemo plus thalidomide for untreated LCH
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with LCH that affects more than one part of your body (multisystem) or multiple spots in one body system (single-system multifocal).
- You have not received any previous treatment for LCH that goes throughout your body (systemic therapy), though local treatments like radiation or surgery are okay.
- You are able to take care of yourself (ECOG performance status 0, 1, or 2).
- You do not have LCH that has spread to your brain or spinal cord (central nervous system).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
This trial tests a targeted drug called trametinib (a MEK inhibitor) for people with Langerhans cell histiocytosis (LCH) that is newly diagnosed, relapsed, or hasn't responded to other treatments. It aims to see if trametinib can better control the disease with fewer side effects.
This trial tests the drug thalidomide for people with symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. It aims to see if thalidomide can help control the disease and improve symptoms like low blood counts or an enlarged spleen.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Hear when a new Langerhans Cell Histiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.